Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sui wai Ling"'
Autor:
Eline L. Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L. W. Koolen, Erik de Blois
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-30 (2024)
Abstract Background In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor effects. As the production and technology has advanced, the avail
Externí odkaz:
https://doaj.org/article/ea3b5e881d0946de8f0c7f54613517f6
Autor:
Sui wai Ling, Astrid A. M. van der Veldt, Mark Konijnenberg, Marcel Segbers, Eline Hooijman, Frank Bruchertseifer, Alfred Morgenstern, Erik de Blois, Tessa Brabander
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Life expectancy of patients with metastatic castration-resistant prostate cancer (mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis of primary prostate cancer, 10–20% of the patients
Externí odkaz:
https://doaj.org/article/7895c2af2d0a42f0969b2758f379db83
Autor:
Sui Wai Ling, Anouk C. de Jong, Ivo G. Schoots, Kazem Nasserinejad, Martijn B. Busstra, Astrid A.M. van der Veldt, Tessa Brabander
Publikováno v:
European Urology Open Science, Vol 33, Iss , Pp 61-71 (2021)
Context: In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA-11) for positron emission tomography (PET) in patients with suspected prostate cancer (PCa) metastasis who are
Externí odkaz:
https://doaj.org/article/9d236f398b7a425faa7d50bf328d90b8
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2166 (2022)
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) hav
Externí odkaz:
https://doaj.org/article/f9b549a85827455b90197b34f0ab5a5a
Autor:
Eline L. Hooijman, Yozlem Chalashkan, Sui Wai Ling, Figen F. Kahyargil, Marcel Segbers, Frank Bruchertseifer, Alfred Morgenstern, Yann Seimbille, Stijn L. W. Koolen, Tessa Brabander, Erik de Blois
Publikováno v:
Pharmaceutics, Vol 13, Iss 5, p 715 (2021)
Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with 177Lu-labeled PSMA-ligands. Radionuclide therapy efficacy may even be improved by using the alpha emitter
Externí odkaz:
https://doaj.org/article/42fb597f2a844a6c90861005882745b7
Autor:
de Jong, Anouk C., Segbers, Marcel, Sui Wai Ling, Graven, Laura H., Mehra, Niven, Hamberg, Paul, Brabander, Tessa, de Wit, Ronald, van der Veldt, Astrid A. M.
Publikováno v:
Journal of Nuclear Medicine; Oct2023, Vol. 64 Issue 10, p1556-1562, 7p
Autor:
Martijn B. Busstra, Tessa Brabander, Astrid A M van der Veldt, Ivo G. Schoots, Anouk C. de Jong, Kazem Nasserinejad, Sui Wai Ling
Publikováno v:
European Urology Open Science, Vol 33, Iss, Pp 61-71 (2021)
European Urology Open Science
European Urology Open Science
Context In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA-11) for positron emission tomography (PET) in patients with suspected prostate cancer (PCa) metastasis who are
Publikováno v:
Pharmaceutics. 14(10)
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) hav
Autor:
Alfred Morgenstern, Stijn L.W. Koolen, Yozlem Chalashkan, Yann Seimbille, Tessa Brabander, Figen F Kahyargil, Sui Wai Ling, Eline L Hooijman, Marcel Segbers, Erik de Blois, Frank Bruchertseifer
Publikováno v:
Pharmaceutics, 13(5):715. Multidisciplinary Digital Publishing Institute (MDPI)
Pharmaceutics
Pharmaceutics, Vol 13, Iss 715, p 715 (2021)
Pharmaceutics
Pharmaceutics, Vol 13, Iss 715, p 715 (2021)
Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with177Lu-labeled PSMA-ligands. Radionu-clide therapy efficacy may even be improved by using the alpha emitter
Autor:
Suzan J W Robroek, Alex Burdorf, M. G. Myriam Hunink, Joost van Rosmalen, Sui Wai Ling, Elisabeth F.C. van Rossum, Tessa A. Kouwenhoven-Pasmooij
Publikováno v:
JMIR Serious Games
Journal of Medical Internet Research (JMIR) Serious Games, 5(2):e6. JMIR Publications Inc.
Journal of Medical Internet Research (JMIR) Serious Games, 5(2):e6. JMIR Publications Inc.
Background: Addressing the obesity epidemic requires the development of effective interventions aimed at increasing physical activity (PA). eHealth interventions with the use of accelerometers and gaming elements, such as rewarding or social bonding,